Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
July 30, 2026 11:16 AM EDT News Briefing Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M ENDPOINTS Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that